Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
The CRUK Scotland Institute invites applications for a Postdoctoral Research Scientist to contribute to developing a PET imaging probe targeting glutamine synthetase in a hepatocellular carcinoma subtype. The post focuses on radiochemistry, preclinical PET imaging, and translational steps toward clinical application.
We seek a PhD holder with PET radiochemistry experience, strong independently driven research skills, and excellent teamwork in a multidisciplinary setting.
Postdoctoral Research Scientist -Professor David Lewis/Thomas Bird
Developing a Hepatocellular Carcinoma Subtype-Specific PET Radiotracer for Preclinical PET Imaging
Salary:from £39,253 to 45,505 subject to experience, plus relocation allowance and visa costs if required.
Contract term:Fixed up to 6 years, subject to successful review at Year 3
About us
The CRUK Scotland Institute is a cancer research institute, situated in Glasgow with approximately 250 researchers split across 30 research groups consisting of PIs, postdoctoral scientists, PhD students and scientific officers. It is one of Europe's leading cancer research centres, supporting cutting-edge work into the molecular mechanisms of cancer development. As well as core support from Cancer Research UK, the Institute also receives an additional third of its total income from external grants and industry collaborations. It has an excellent reputation for fundamental cancer research, including world-class metabolism studies and renowned in vivo modelling of tumour growth and metastasis.
Project outline
Hepatocellular carcinoma (HCC) is a highly heterogeneous and often treatment-resistant cancer, with no clinically validated biomarkers to guide patients toward the most effective targeted therapies. A clinically important HCC subtype driven by activation of the canonical Wnt/β-catenin pathway is strongly immune evasive and frequently resistant to immunotherapy. Despite its significance, this subtype cannot currently be reliably identified using genetic profiling alone.
This Jules Thorne funded programme brings together a multidisciplinary team to develop the first subtype specific precision approach for HCC. The project integrates metabolic biomarker discovery and validation, state of the art GEMMs and patient derived organoid models, clinical sample analysis from prospective patient cohorts, and advanced radiochemistry and metabolic PET imaging. Together, these approaches aim to establish the first subtype specific therapeutic strategy for early phase HCC clinical trials.
We are seeking a highly motivated Postdoctoral Research Scientist to contribute to the development of a PET imaging probe targeting glutamine synthetase (GS), a downstream effector of canonical Wnt/β catenin signalling, to detect this tumour subtype in vivo. This project builds on the recent discovery of a noncanonical enzymatic function of GS (Villar et al., Nature Chemical Biology, 2023). The successful candidate will work on radiotracer synthesis, preclinical PET/MRI imaging, and ultimately clinical translation.
Main Duties & Responsibilities:
Knowledge/Qualifications
Essential Criteria
Desirable Criteria
This role offers a unique opportunity to contribute to a cutting-edge translational cancer research programme, with the potential to make a meaningful impact on clinical patient management. If you are passionate about radiochemistry and advancing our understanding cancer metabolism, we encourage you to apply.
Postdoc support
Postdocs are key members of our research community, and we offer them a range of opportunities to train and develop as researchers while they are with us:
For informal enquiries, please email Professor David Lewis (David.Lewis@glasgow.ac.uk) / Thomas Bird (t.bird@crukscotlandinstitute.ac.uk)
Equality, Diversity and Inclusion
Our vision is to build and maintain a diverse and inclusive research culture based on our shared values of Innovate, Respect, Integrity, Teamwork and Excellence. These values, which underpin our behaviours and everything we do, allow all our people to realise their full potential. The diversity of our staff and students is also what makes the Institute such a vibrant place to work and advance discoveries in cancer research. Family friendly policies, our collaborative ethos, a focus on good mental health and well-being and opportunities for all help to create an enjoyable and inclusive workplace where your voice matters.
Employee Benefits
Closing Date: 18th September 2026